Home › Melanoma › Vermont › Burlington
Melanoma clinical trials in Burlington, VT
3 studies for Melanoma are looking for participants at sites in and around Burlington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
RecruitingPhase 3
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- University of Vermont and State Agricultural College, Burlington
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Recruiting
- University of Vermont Medical Center, Burlington
- University of Vermount and Sate Agricultural College, Burlington
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX61 studies
- New York City, NY41 studies
- Nashville, TN34 studies
- Los Angeles, CA34 studies
- Pittsburgh, PA31 studies
- Boston, MA25 studies
- St. Louis, MO23 studies
- Durham, NC22 studies
- Philadelphia, PA22 studies
- Tampa, FL21 studies
- Columbus, OH21 studies
- Dallas, TX21 studies
Other studies in Burlington
- Acute Myeloid Leukemia7 studies
- Heart Failure7 studies
- COPD5 studies
- Leukemia5 studies
- Cancer (all types)5 studies
- Breast Cancer4 studies
- Metastatic Cancer4 studies
- Lung Diseases4 studies
- Non-Small Cell Lung Cancer4 studies
- Parkinson's Disease4 studies
- Cystic Fibrosis4 studies
- Cardiovascular Disease4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.